SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
208 hedge funds and large institutions have $1.09B invested in SANGAMO THERAPEUTICS INC in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 54 increasing their positions, 73 reducing their positions, and 17 closing their positions.
235% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 17
22% more funds holding
Funds holding: 170 → 208 (+38)
14% more capital invested
Capital invested by funds: $955M → $1.09B (+$131M)
0.18% more ownership
Funds ownership: 66.07% → 66.25% (+0.18%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
26% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 73
37% less call options, than puts
Call options by funds: $18.4M | Put options by funds: $29.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52.7M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$27.6M |
| 3 |
Morgan Stanley
New York
|
+$17.5M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$12.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCS
Crosspoint Capital Strategies
Orinda,
California
|
-$44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.6M |
| 3 |
D.E. Shaw & Co
New York
|
-$22.1M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$21.5M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$19.2M |
SGMO Hedge Fund Activity: Q1 2018 in Review
208 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2018, worth a combined $1.09B — up 14% from $955M a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new SGMO positions and 17 closed out — a net gain of 40 holders — while 54 added to existing stakes and 73 trimmed.
The largest buyer was Vanguard Group, adding an estimated $52.7M. The largest seller was Crosspoint Capital Strategies, exiting entirely with an estimated $44M sold.
- 208 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2018, up from 170 in Q4 2017.
- Funds reported $1.09B of SANGAMO THERAPEUTICS INC stock for Q1 2018, up 14% quarter-over-quarter.
- 57 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2018 and 17 closed out, a net change of +40 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2018 was Vanguard Group, an estimated $52.7M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2018 was Crosspoint Capital Strategies, an estimated $44M sold.
Based on aggregated 13F filings for Q1 2018.